Add-on therapy with topiramate in drug-resistant epilepsy
Article Type:
Research/Original Article (دارای رتبه معتبر)
Abstract:
Background
therapy The present study was conducted to evaluate the efficacy and side effects of topiramate as an add-on therapy in drug-resistant ( intractable) epilepsies .
Materials and methods
hospital with refractory epilepsy were enrolled. The study population included 14 girls and 28 boys, aged 1-15 years. Seizure attacks were not controlled despite receiving 4-13 drugs (mean 9). Topiramate was added to the patient's drug in a 4-week titration regimen (1 st week 3, 2 nd week 5, 3 rd week 7, and 4 th week 9mg/kg). Then , after 3 months he/she was reevaluated .
Results
progressive myoclonic epilepsy were revealed in 14 (34%), 8(19%), 16(38%), and 4(9%), respectively . After the 3-month add-on therapy with topiramate, 17% became seizure-free and the frequency of seizure attacks decreased by 50% in 26% of the patients , however, attacks were exacerbated in 5%. Fortunately, hematologic, renal or hepatic side effects were not reported, however, mild transient neurologic complications were observed in 12% of the patients .
Conclusion
intractable seizures
Keywords:
Language:
Persian
Published:
Journal of Research In Medical Sciences, Volume:29 Issue: 2, 2005
Page:
147
magiran.com/p270115
دانلود و مطالعه متن این مقاله با یکی از روشهای زیر امکان پذیر است:
اشتراک شخصی
با عضویت و پرداخت آنلاین حق اشتراک یکساله به مبلغ 1,390,000ريال میتوانید 70 عنوان مطلب دانلود کنید!
اشتراک سازمانی
به کتابخانه دانشگاه یا محل کار خود پیشنهاد کنید تا اشتراک سازمانی این پایگاه را برای دسترسی نامحدود همه کاربران به متن مطالب تهیه نمایند!
توجه!
- حق عضویت دریافتی صرف حمایت از نشریات عضو و نگهداری، تکمیل و توسعه مگیران میشود.
- پرداخت حق اشتراک و دانلود مقالات اجازه بازنشر آن در سایر رسانههای چاپی و دیجیتال را به کاربر نمیدهد.
In order to view content subscription is required
Personal subscription
Subscribe magiran.com for 70 € euros via PayPal and download 70 articles during a year.
Organization subscription
Please contact us to subscribe your university or library for unlimited access!